Cosmos electronic health records covered 92.4 million US adults with no recorded type 2 diabetes or qualifying obesity, 2021 to 2025. Prescribing of liraglutide, semaglutide or tirzepatide rose from 0.1% in 2021 to 1.5% in 2025. Of the 1.13 million prescribed, 35.1% had a normal body mass index.
Why it is interesting: A third of recipients were of normal weight, outside the groups where the benefit is established.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.